BRAF and neoplasm: Given the rapid response to targeted therapy, accompanied by a dramatic decrease in overall tumor load, the decision to commence targeted therapy in patients with BRAF V600 mutations may be favored in the context of symptomatic disease and the presence of adverse prognostic markers, including raised serum LDH concentrations, ECOG performance status> 1, younger patients, and those with brain and/or metastases at multiple sites (8, 9).